thioraviroc

Thioraviroc is a small molecule CCR5 antagonist developed by the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, for the treatment of HIV-1 infection. It is a sulfur-containing analog of maraviroc, specifically designed to inhibit the entry of R5-tropic HIV-1 strains into host cells. By binding to the CCR5 coreceptor on the surface of CD4+ T lymphocytes, thioraviroc prevents the viral envelope glycoprotein gp120 from binding, which is a critical step for viral fusion and entry. Preclinical and clinical studies in China have indicated that thioraviroc possesses potent antiviral activity and a favorable safety profile, positioning it as a potential therapeutic option for patients with CCR5-tropic HIV-1.

Other names

thio-maraviroc